

# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY



(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

REC'D 09 DEC 2005

WIPO

PCT

Applicant's or agent's file reference PC25264A	<b>FOR FURTHER ACTION</b>		See Form PCT/PEA/416
International application No. PCT/IB2004/002919	International filing date (day/month/year) 06.09.2004	Priority date (day/month/year) 17.09.2003	
International Patent Classification (IPC) or national classification and IPC C07D207/34, A61K31/40, A61P3/06			
Applicant WARNER-LAMBERT COMPANY LLC et al.			
<p>1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 6 sheets, including this cover sheet. ✓</p> <p>3. This report is also accompanied by ANNEXES, comprising:</p> <p>a. <input checked="" type="checkbox"/> sent to the applicant and to the International Bureau) a total of 2 sheets, as follows: ✓</p> <p><input checked="" type="checkbox"/> sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).</p> <p><input type="checkbox"/> sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.</p> <p>b. <input type="checkbox"/> (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).</p>			
<p>4. This report contains indications relating to the following items:</p> <p><input checked="" type="checkbox"/> Box No. I Basis of the opinion</p> <p><input type="checkbox"/> Box No. II Priority</p> <p><input checked="" type="checkbox"/> Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p><input type="checkbox"/> Box No. IV Lack of unity of invention</p> <p><input checked="" type="checkbox"/> Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p><input type="checkbox"/> Box No. VI Certain documents cited</p> <p><input type="checkbox"/> Box No. VII Certain defects in the international application</p> <p><input checked="" type="checkbox"/> Box No. VIII Certain observations on the international application</p>			
Date of submission of the demand 19.10.2004 ✓		Date of completion of this report 08.12.2005	
Name and mailing address of the International preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Authorized Officer  Seymour, L Telephone No. +49 89 2399-8694 	

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.  
PCT/IB2004/002919

---

## Box No. I Basis of the report

---

1. With regard to the **language**, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.
  - ☐ This report is based on translations from the original language into the following language , which is the language of a translation furnished for the purposes of:
    - ☐ international search (under Rules 12.3 and 23.1(b))
    - ☐ publication of the international application (under Rule 12.4)
    - ☐ international preliminary examination (under Rules 55.2 and/or 55.3)
2. With regard to the **elements\*** of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):*

### Description, Pages

1-16 as originally filed

### Claims, Numbers

1-16 received on 20.07.2005 with letter of 13.07.2005

### Drawings, Sheets

1/4-4/4 as originally filed

- ☐ a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing

3. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/figs
- ☐ the sequence listing (*specify*):
- ☐ any table(s) related to sequence listing (*specify*):

4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/figs
- ☐ the sequence listing (*specify*):
- ☐ any table(s) related to sequence listing (*specify*):

\* If item 4 applies, some or all of these sheets may be marked "superseded."

**INTERNATIONAL PRELIMINARY REPORT  
ON PATENTABILITY**

International application No.  
PCT/IB2004/002919

**Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application,  
☒ claims Nos. 15 with respect to industrial applicability

because:

- ☒ the said international application, or the said claims Nos. 15 with respect to industrial applicability relate to the following subject matter which does not require an international preliminary examination (specify):

**see separate sheet**

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☐ no international search report has been established for the said claims Nos.
- ☐ the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:
- |                            |  |
|----------------------------|--|
| the written form           | <input type="checkbox"/> has not been furnished            |
|                            | <input type="checkbox"/> does not comply with the standard |
| the computer readable form | <input type="checkbox"/> has not been furnished            |
|                            | <input type="checkbox"/> does not comply with the standard |
- ☐ the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-*bis* of the Administrative Instructions.
- ☐ See separate sheet for further details

**INTERNATIONAL PRELIMINARY REPORT  
ON PATENTABILITY**

International application No.  
PCT/IB2004/002919

---

**Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

---

1. Statement

Novelty (N)	Yes: Claims	1-16
	No: Claims	
Inventive step (IS)	Yes: Claims	1-16
	No: Claims	
Industrial applicability (IA)	Yes: Claims	1-14,16
	No: Claims	

2. Citations and explanations (Rule 70.7):

**see separate sheet**

---

**Box No. VIII Certain observations on the international application**

---

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**

**INTERNATIONAL PRELIMINARY  
REPORT ON PATENTABILITY  
(SEPARATE SHEET)**

International application No.

PCT/IB2004/002919

**Re Item III**

Claim 15 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of this claim (Article 34(4)(a)(I) PCT).

**Re Item V**

1. Reference is made to the following documents:

D1: US-B-6 583 2951      D2: WO-A-02 43667      D3: US-A-4 681 893

2. The subject-matter of the present claims is new (Article 33(2) PCT), since they do not disclose crystalline atorvastatin free acid: in D1 the free acid of atorvastatin is an oil, in D2 it is obtained as a solid mixture with the lactone form, and in D3 it is obtained as a crude material which is not further purified.
3. Document D1 is regarded as being the closest prior art. The present atorvastatin free acid differs from that disclosed in D1 in that it is a crystalline solid rather than an oil (see D1, example 22), which results in a purer, more stable product (see present description, p. 3, lines 27-29 and p. 11, lines 13-17).

The problem to be solved by the present invention may be regarded as the provision of a purer, more stable form of atorvastatin.

Previously, this problem has been solved by formation of salts (see D1-D3). The solution to this problem proposed in the present claims is considered as involving an inventive step (Article 33(3) PCT) since none of the prior art suggests the formation of a crystalline form of atorvastatin free acid.

4. Industrial applicability (Article 33(4) PCT)

For the assessment of the present claim 15 on the question whether it is industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO,

**INTERNATIONAL PRELIMINARY  
REPORT ON PATENTABILITY  
(SEPARATE SHEET)**

International application No.

PCT/IB2004/002919

for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

**Re Item VIII**

Claims 2-13 comprise all the features of claims 1 and 16 and are therefore not appropriately formulated as claims dependent on the latter (Article 6 and Rule 6.4 PCT). In addition a reference to claim 1 has been omitted from claim 14.

Contrary to Article 6 PCT, claim 1 does not contain the full chemical name of atorvastatin (cf. p. 1, lines 6-8).



Patent  
International Application No.: PCT/IB2004/002919  
Attorney Docket No. PC25264A PCT  
Page 2 of 3

### CLAIMS

1. A crystalline atorvastatin free acid.
2. A crystalline Form A atorvastatin free acid or a hydrate thereof having a X-ray powder diffraction pattern containing the following  $2\theta$  values measured using  $\text{CuK}\alpha$  radiation: 8.9, 20.6, 22.5, or 25.9.
3. A crystalline Form A atorvastatin free acid or a hydrate thereof having a X-ray powder diffraction pattern containing the following  $2\theta$  values measured using  $\text{CuK}\alpha$  radiation: 4.7, 6.0, 8.9, 9.1, 9.4, 13.2, 14.1, 17.8, 18.1, 18.9, 19.9, 20.2, 20.6, 21.8, 22.1, 22.5, 23.7, 25.9, and 26.7.
4. A crystalline Form A atorvastatin free acid ~~hydrate thereof~~ having a X-ray powder diffraction pattern containing the following  $2\theta$  values measured using  $\text{CuK}\alpha$  radiation: 8.9, 20.6, 22.5, or 25.9.
5. A crystalline Form A atorvastatin free acid ~~hydrate thereof~~ having a X-ray powder diffraction pattern containing the following  $2\theta$  values measured using  $\text{CuK}\alpha$  radiation: 4.7, 6.0, 8.9, 9.1, 9.4, 13.2, 14.1, 17.8, 18.1, 18.9, 19.9, 20.2, 20.6, 21.8, 22.1, 22.5, 23.7, 25.9, and 26.7.
6. A crystalline Form A atorvastatin free acid or a hydrate thereof characterized by solid-state  $^{13}\text{C}$  nuclear magnetic resonance having the following chemical shifts expressed in parts per million: 18.1, 18.8, 20.5, and 21.2.
7. A crystalline Form A atorvastatin free acid or a hydrate thereof characterized by solid-state  $^{13}\text{C}$  nuclear magnetic resonance having the following chemical shifts expressed in parts per million: 161.5, 163.6, 166.3, 167.1, 174.3, and 180.6.
8. A crystalline Form A atorvastatin free acid or a hydrate thereof characterized by solid-state  $^{13}\text{C}$  nuclear magnetic resonance having the following chemical shifts expressed in parts per million: 18.1, 18.8, 20.5, 21.2, 25.0, 25.5, 26.2, 26.8, 37.1, 38.9, 40.0, 40.6, 41.8, 42.9, 43.5, 65.3, 68.6, 69.1, 70.0, 71.3, 112.3, 113.7, 115.1, 116.4, 118.4, 119.3, 121.6, 123.3, 125.4, 128.0, 128.8 (shoulder), 130.0, 132.9, 134.1, 135.2, 137.9, 140.7, 141.8, 161.5, 163.6, 166.3, 167.1, 174.3, and 180.6.
9. A crystalline Form A atorvastatin free acid or a hydrate thereof characterized by solid-state  $^{19}\text{F}$  nuclear magnetic resonance having the following chemical shifts expressed in parts per million: -114.1, -112.6, -110.6, ~~or~~ and -105.6.
10. A crystalline Form A atorvastatin free acid ~~hydrate thereof~~ characterized by solid-state  $^{19}\text{F}$  nuclear magnetic resonance having the following chemical shifts expressed in parts per million: -114.1, -112.6, -110.6, ~~or~~ and -105.6.

Patent  
International Application No.: PCT/IB2004/002919  
Attorney Docket No. PC25264A PCT  
Page 3 of 3

11. A crystalline Form B atorvastatin free acid or a hydrate thereof having a X-ray powder diffraction pattern containing the following  $2\theta$  values measured using  $\text{CuK}\alpha$  radiation: 8.6, 17.4, 21.1, ~~21.5~~ and 21.5.
12. A crystalline Form B atorvastatin free acid or a hydrate thereof having a X-ray powder diffraction pattern containing the following  $2\theta$  values measured using  $\text{CuK}\alpha$  radiation: 4.6, 5.9, 8.6, 9.3, 13.3, 14.1, 17.4, 17.7, 18.0, 18.8, 19.3, 19.8, 20.2, 21.1, 21.5, 21.9, and 23.6.
13. A crystalline Form B atorvastatin free acid having a X-ray powder diffraction pattern containing the following  $2\theta$  values measured using  $\text{CuK}\alpha$  radiation: 4.6, 5.9, 8.6, 9.3, 13.3, 14.1, 17.4, 17.7, 18.0, 18.8, 19.3, 19.8, 20.2, 21.1, 21.5, 21.9, and 23.6.
14. A pharmaceutical composition comprising crystalline atorvastatin free acid in admixture with at least one pharmaceutically acceptable excipient, diluent, or carrier.
15. A method of treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to Claim 1 in unit dosage form.
16. A crystalline atorvastatin free acid hydrate.